The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

The first two groups included 36,082 patients using GLP-1 receptor agonists and 234,028 patients using DPP-4 inhibitors ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

However, both GLP-1s and SGLT2 inhibitors may offer similar antidepressant benefits, researchers noted. The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older ...

The first cohort included 36,082 GLP-1 receptor agonist users (dulaglutide [Trulicity], exenatide, liraglutide [Victoza], lixisenatide, and semaglutide) and 234,028 DPP-4 inhibitor users ...

Opens in a new tab or window Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for ...

The first cohort comprised individuals who started and continued either a GLP-1 receptor agonist or DPP-4 inhibitor for the first time between January 1, 2007, and December 31, 2020. The second ...

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target ...

In one arm of the study, researchers compared more than 36,000 people prescribed a GLP-1 drug against more than 234,000 patients taking DPP-4 inhibitors for their diabetes between 2007 and 2020.

Opens in a new tab or window New GLP-1 receptor agonist users did not have an excess risk for suicidality compared with DPP-4 inhibitor and SGLT2 inhibitor users. They also didn't have an excess ...